Anxiety Disorders & Depression Treatment Market Overview
Anxiety Disorders & Depression Treatment Market Size is estimated to reach $19.5 billion by 2027. Furthermore, it is poised to grow at a CAGR of 2.8% over the forecast period of 2022-2027. Anxiety disorder and depression are the most prevalent mental health conditions. As per WHO, globally 5% of adults suffer from depression. Anxiety disorders affect 13.3% of people in the United States alone, making it the most common group of mental diseases. Depression is the leading cause of disability and a major contributor to the overall global burden of diseases. Depression and anxiety give symptoms like poor concentration, feeling of excessive guilt or low self-worth, hopelessness, thoughts about death or suicide, disrupted sleep, changes in appetite or weight, and feeling especially tired or low in energy. Anxiety disorders & depression are diagnosed by physical exam, lab test, psychiatric evaluation, and criteria by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). There are various types of depression such as anxious distress, mixed features, melancholic features, atypical features, psychotic features, catatonia, peripartum onset, and seasonal pattern also other disorders cause depression symptoms such as Bipolar I and II disorders, Cyclothymic disorders, and others as per mayo clinic. Anxiety and depression can be cured by Selective serotonin reuptake inhibitors (SSRIs), Serotonin-norepinephrine reuptake inhibitors (SNRIs), Atypical antidepressants, Tricyclic presents, Monoamine oxidase inhibitors (MAOIs), antidepressants, anxiolytics, anticonvulsants, noradrenergic agents, atypical antipsychotics and by the use of other medication. About 280 million people around the world live in depression as per WHO. Such increasing prevalence of mental diseases and health burden owing to such diseases helps to grow the Anxiety Disorders & Depression Treatment Market over the forecast period 2022-2027.
The report: “Anxiety Disorders & Depression Treatment Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments of the Anxiety Disorders & Depression Treatment Market.
By Drugs: Antidepressants,
Anxiolytics, Anticonvulsants, Noradrenergic Agents, and Atypical
By Indication: Anxiety, Depression.
By Therapies: Electroconvulsive Therapy (ECT), Cognitive Behaviour Therapy (CBT), Psychotherapy, Deep Brain Stimulation, Transcranial Magnetic Stimulation (TMS), and Cranial electrotherapy stimulation (CES).
By Device: Cranial electrotherapy stimulator, Fisher-Wallace stimulator.
By Application: Phobia, Major Depressive Disorder, Obsessive-Compulsive Disorder (OCD), Post-traumatic stress disorder, and Others.
By Distribution Channels: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy.
By Geography: North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and the Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America), and Rest of the World (the Middle East, and Africa).
- Geographically, North America held a dominant market share in the year 2021 attributed to an increase in the number of cases of anxiety and depression.
- The increasing prevalence of mental disorders helps to grow the Anxiety Disorders & Depression Treatment Market over the forecast period 2022-2027.
- However, a higher chance of side effects and an increasing number of suicides after taking anti-depressant may stymie the growth of the Anxiety Disorders & Depression Treatment Market Report.
- A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Anxiety Disorders & Depression Treatment Market Report.
Anxiety Disorders & Depression Treatment Market: Market Share (%) by Region, 2021
For More Details on This Report - Request for Sample
Anxiety Disorders & Depression Treatment Market Segmentation Analysis By Drugs
Anxiety Disorders & Depression Treatment Market based on the drugs can be further segmented into Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents, and Atypical Antipsychotics. Antidepressants held a dominant share in 2021 and are expected to be the fastest growing with a CAGR of 3.2% over the forecast period of 2022-2027. Antidepressant helps to relieve long-term symptoms of chronic depressive disorder (dysthymia) and chronic depression. According to the Centers for Disease Control and Prevention (CDC), the percentage of people aged 12 years and over using antidepressants is increasing in the United States. Adolescents aged 12 to 17 years old have the highest rate of depression in the United States. Each year about 17.5 million U.S men and women are diagnosed with depression and nearly 58% were prescribed an antidepressant. Owing to such factors anti-depressant segment helps to grow the Anxiety Disorders & Depression Treatment Market.
Anxiety Disorders & Depression Treatment Market Segmentation Analysis By Indication
Anxiety Disorders & Depression Treatment Market based on indication can be further segmented as Anxiety and Depression. Anxiety held a dominant share in 2021. This is owing to most of the population around the world living hectic lifestyles and under stress. According to CDC, from august 2020 to February 2021, the number of adults detected with symptoms and anxiety or depressive disorders increased from 36% to 42%. Anxiety is the most common mental disorder affecting 40 million people in the US population according to the (Alcohol and Drug Abuse Administration) ADAA. Owing to such increasing prevalence of anxiety around the world helps to grow the Anxiety Disorders & Depression Treatment Market
However, the Depression segment is estimated to grow by 3.4% in the forecast period of 2022-2027. Owing to the past covid-19 situation number of people under depression is increased. As per a research article published in ‘BMC’ in 2020, people who are kept in isolation and quarantine experience a significant level of anxiety, anger, confusion, and stress that leads towards depression. Suicide is linked with depression every year. 703,000 peoples attempt suicide as per WHO, and people between the ages group of 15 to 29 years mostly attempt suicide. According to The Lancet journal, India accounts for about 15% of global mental, neurological, and substance addiction diseases. Such increasing prevalence of depression and one of the leading causes of death helps to grow the Anxiety Disorders & Depression Treatment Market over the forecast period 2022-2027.
Anxiety Disorders & Depression Treatment Market Segmentation Analysis by Geography
The Anxiety Disorders & Depression Treatment Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held the dominant share of 34% in 2021. This is owing to the high prevalence of anxiety and depression among the U.S population. After the impact of Covid-19, the rate of anxiety and depression in U.S adults increased by 4 times from April 2020 to August 2021 than in 2019 according to American Psychological Association. Also, the presence of major market players and the launch and expansion of their innovative product helps to grow the Anxiety Disorders & Depression Treatment Market.
Furthermore, Asia-Pacific is estimated to be the fastest-growing over the forecast period 2022-2027, this is owing to the increasing prevalence of mental diseases in the Asia-Pacific region. The top five mental health problems in the Asia-Pacific are depression, anxiety, Post-Traumatic Stress Disorder (PTSD), suicidal behavior, and substance abuse disorder as per WHO. According to a research report published in Springer in 2022, depression had the highest prevalence (59.2%), followed by anxiety (55.1%) and stress (3.4%). Such factors help to grow Asia-Pacific Anxiety Disorders & Depression Treatment Market over the forecast period 2022-2027.
Anxiety Disorders & Depression Treatment Market Drivers
Raising Prevalence of Anxiety Disorders Helps to Drive Market Growth
Owing to a hectic and busy lifestyle, people are living under stress, anxiety and depression. Stress causes fear, anger, sadness, frustration, and loss of appetite. As per WHO, approximately 280 million people in the world live under depression. Suicides due to depression are the fourth leading cause of death in 15-29 years old age, about 46000 children between the age of 10 to 19 take their lives every year. Globally 2% of government health budgets are used for mental health. Around 275 million people suffer from anxiety disorders which are around 4% of the global population and around 62% of patients who suffers are female, according to the weforum organization. Such increasing prevalence of anxiety around the world helps to grow the anxiety disorder and depression treatment market.
Increasing Healthcare Facilities and Expenditure Fuels Market Growth
Increasing expenditure on healthcare by people and government and increasing awareness about mental illness help to drive market growth. In May 2022, the Biden-Harris Administration is taking the initiative to strengthen the mental health of all Americans, which is a key part of the President’s Unity Agenda which awarded $22 million to the Health Resources and Services Administration (HRSA) to grow the behavioral health workforce, nearly $225 million for behavioral health professional and paraprofessional education. In 2022, 0.8% of the total health budget of India went towards mental health and that is $88 million as per the report published by United for Global Mental Health Organisation. Such increasing government attention toward mental health allows to drive the market.
Anxiety Disorders & Depression Treatment Market Challenges
Risk of Side Effects by Medicine and Increasing Number of Suicides After Taking Anti-depressant Hampers Market Growth
To treat anxiety disorder and depression, doctors give neuro medicines that cause side effects like trouble with short-term memory, multi-tasking, reading comprehension, and concentration. According to the Lancet journal, 74.13% of patients experienced anti-depressant side effects, where insomnia (17.05%), and anxiety (17.05%) are common. As per a research published in NCBI, in 2019, 38% and approximately 700 patients surveyed experienced one or more side effects as a result of taking an SSRI anti-depressant. Also, a patient who takes SSRI may experience side effects such as violent behavior, mania, or aggression which can lead to suicide as per drug watch. According to a research study by frontiers in public health organizations, there were 1277 suicides, and about one-third belong to taking an anti-depressant. Such increasing side effects and an increasing number of suicides after taking neuro medicines may hinder the market growth.
Anxiety Disorders & Depression Treatment Industry Outlook
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Anxiety Disorders & Depression Treatment Market. The top 10- Anxiety Disorders & Depression Treatment Market companies are-
- Amicogen, Inc.
- BioCell Technology LLC
- Capsugel Belgium NV
- Catalent, Inc.
- ChinaTech Peptide Co. Ltd.
- GELITA AG
- InterHealth Nutraceuticals, Inc.
- Nitta Gelatin, Inc
- Norland Products, Inc.
- In March 2022, Amicogen Inc. started construction on a cell culture medium factory to produce biopharmaceuticals in Zone 5 of Songdo International City, Korea. After completion of the project company will be able to produce 4 million liters of media per year.
- In November 2021, BioCell Technologies developed the platform RapidNA, to quickly produce a large amount of RNA in New Zealand. The production occurs in the south Auckland production facility. In addition to the RNA platform, BioCell will install New Zealand’s first high-speed automated filling machine at its Papatoetoe production facility with the ability to fill up 100 million vaccine doses on site.
- In March 2021, Capsugel Belgium known as Lonza expands its capsule manufacturing capacity with a $93 million investment in its capsule and health ingredients division, to produce 30 billion capsules annually. This investment increase 15% the capacity of the capsule and health ingredients division.
Report Code: FBR 91028
Report Code: CMR 62973
For more Lifesciences and Healthcare Market reports, please click here